4XC1.F · KalVista Pharmaceuticals, Inc

-

Please sign in to comment on 4XC1.F

1 Comment

Admin

5 years ago

KalVista Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 0.3% below its 200 day moving average.

From a valuation standpoint, the stock is 91.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 117.4.

KalVista Pharmaceuticals, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has dropped by 8.1% to $-10M since the same quarter in the previous year.

Finally, its free cash flow grew by 42.0% to $-8M since the same quarter in the previous year.

Based on the above factors, KalVista Pharmaceuticals, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	US4834971032
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Dividend Yield	None
Beta	-0.29
Market Cap	794M

ABOUT

KalVista Pharmaceuticals, Inc

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

4XC1.F · KalVista Pharmaceuticals, Inc

-

KalVista Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest KalVista Pharmaceuticals, Inc using a moving average strategy